Stonepine Capital Management LLC bought a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 48,012 shares of the biotechnology company’s stock, valued at approximately $313,000. Ironwood Pharmaceuticals comprises approximately 0.3% of Stonepine Capital Management LLC’s holdings, making the stock its 24th biggest holding.
Other hedge funds also recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its stake in Ironwood Pharmaceuticals by 152.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 2,645 shares in the last quarter. CWM LLC lifted its stake in Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 2,345 shares in the last quarter. SG Americas Securities LLC purchased a new position in Ironwood Pharmaceuticals during the 1st quarter valued at about $91,000. GAMMA Investing LLC grew its position in Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 8,156 shares in the last quarter. Finally, EntryPoint Capital LLC lifted its position in shares of Ironwood Pharmaceuticals by 517.4% during the first quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 8,874 shares in the last quarter.
Insider Activity at Ironwood Pharmaceuticals
In related news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the sale, the insider now directly owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 12.90% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Report on Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Stock Up 2.5 %
Shares of IRWD opened at $4.12 on Tuesday. The company has a market capitalization of $644.90 million, a price-to-earnings ratio of -0.61 and a beta of 0.49. Ironwood Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $15.70. The stock has a 50 day moving average price of $5.07 and a 200 day moving average price of $6.43.
Ironwood Pharmaceuticals Profile
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.
See Also
- Five stocks we like better than Ironwood Pharmaceuticals
- Stock Sentiment Analysis: How it Works
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- How to Invest in Biotech Stocks
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- The 3 Best Retail Stocks to Shop for in August
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report).
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.